Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Medigenomix Licenses Amplification Technology from Orion Diagnostica

NEW YORK (GenomeWeb News) – Eurofins Mediogenomix has licensed co-exclusive rights to Orion Diagnostica's strand invasion-based amplification (SIBA) technology, the firms announced today.

Espoo, Finland-based Orion Diagnostica owns the global rights for the SIBA isothermal nucleic acid detection technology in all fields, the partners noted. Financial and other terms of the agreement were not disclosed.

"The SIBA technology and the associated expertise of Orion Diagnostica are an excellent fit for Eurofins," Peter Persigehl, managing director of Eurofins Medigenomix, which is part of the Eurofins Scientific group. "The cooperation will allow us to broaden Eurofins' portfolio with innovative analytical solutions particularly in the area of DNA-based authenticity testing for food and related products."

The SIBA technology relies on the recombinase-dependent invasion of an oligonucleotide into the target nucleic acid, leading to dissociation of the double-stranded nucleic acid. This enables specific primers to amplify the target exponentially by the action of the polymerase, according to Orion.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.